18 and older, any sex, with Mucous Membrane Pemphigoid or Cicatrizing Conjunctivitis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Treatment ResponsePrimary· 8 weeks
Treatment response of ocular inflammation based on conjunctival injection measured by ophthalmologic exam of the palpebral conjunctiva. Each eye is divided into quadrants and each quadrant is scored from 0 (white and quite) to 3 (severe). The score will be the sum of all 4 quadrants for a total score of 0-12 for each eye. A clinically meaningful response will be defined as a ≥30% reduction in the total score for both eyes.
Group
Value
95% CI
Baricitinib
1
Antiproliferative
0
Adverse events — posted to ClinicalTrials.gov
Time frame: Averse events were recorded for 2 weeks for the participant in the standard of care arm and 8 months for the participant on the baricitinib arm..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Baricitinib
Serious: 1/1 (100%)
Deaths: 0/1
Antiproliferative
Serious: 1/1 (100%)
Deaths: 0/1
Serious adverse events (2 terms)
Reaction
System
Baricitinib
Antiproliferative
Anaphylaxis
Respiratory, thoracic and mediastinal disorders
—
—
Malignancy
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ocular mucous membrane pemphigoid (MMP) is an autoimmune, scarring conjunctivitis that can lead to vision loss and permanent disability. It is a rare disorder with an estimated incidence of 1 in 60,000. There are currently no FDA-approved medications for the treatment of mucous membrane pemphigoid, highlighting a clear unmet need.
At present, moderate to severe disease requires off-label use of potent immunosuppressive agents, such as oral anti-proliferatives (methotrexate, azathioprine, and mycophenolate), rituximab (RTX) or cyclophosphamide (CyC). Recently, Janus kinase (JAK) inhibition with baricitinib or tofacitinib been reported to be successful in one case of ocular MMP.
This is a randomized, single-masked, two-arm study of baricitinib vs anti-proliferatives for ocular MMP.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 7 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05263505.